Host: The Japanese Pharmacological Society, The Japanese Society of Clinical Pharmacology
Name : WCP2018 (18th World Congress of Basic and Clinical Pharmacology)
Location : Kyoto
Date : July 01, 2018 - July 06, 2018
BACKGROUND: Serotonin, also known as 5-hidroxytriptamine is a monoamine found in both, central and peripheral nervous system. Recently, it has been suggested that serotonin has a modulating effect over glucose metabolism, being 5 HT2A the main receptor involved in glycemia reduction. Due to this fact, we decided to evaluate quipazine effect over glycemia, since it was the first synthetic serotoninergic agonist with affinity for 5-HT 2 and 5-HT3.
METHODS: Oral glucose tolerance test (OGTT, 2 g/kg) were performed in healthy male Wistar rats in order to assess quipazine effect using 5, 10, and 20 mg/Kg doses. Once the effect of quipazine over glycemia was determined we decided to stay on 10 mg/Kg dose, which was used to pharmacologically assess the role of 5-HT2 in the anti-hyperglycemic effect of quipazine using OGTT. Animals were previously treated with pelanserine (5-HT2 antagonist, 2.5 mg/kg i.p.). Later, insulin determining OGTT were performed (insulin (Rat) ELISA; ALPCO Immunoassays) in normal rats in order to determine if a quipazine-triggered increase in insulin release have been produced. Finally, OGTT were performed in rats with streptozotocin (60 mg/Kg) induced diabetes type 1 to assess the role of insulin in the anti-hyperglycemic effect of quipazine.
RESULTS AND CONCLUSIONS: A dose of 10 mg/Kg of quipazine was the one that showed the best ant-hyperglycemic effect in OGTT when increase in plasmatic insulin in rats treated with 10 mg/Kg of quipazine, compared with control. In the diabetic rats model we found that anti-hyperglycemic effect of quipazine was diminished which suggest that in addition to insulin release after a glucose charge, there should be another mechanisms .This opens a gate for the study of quipazine analogues for their use in the treatment of diseases such as DT2 and SM, since quipazine itself has adverse gastrointestinal effects.
